RIPE-KG · Version 1.1.0 · Resource
ripekg:work/RIPEW7882272F2A6FA8D6
https://w3id.org/ripe/ripe-kg/work/RIPEW7882272F2A6FA8D6
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1111%2Fdom.15802Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW7882272F2A6FA8D6Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
ripekg:work/RIPEW7882272F2A6FA8D6Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
dcterms:title |
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
ripekg:work/RIPEW7882272F2A6FA8D6Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
rdf:type |
node1 |
ripekg:work/RIPEW7882272F2A6FA8D6Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/RIPEW7882272F2A6FA8D6Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
rdf:type |
rdfs:Resource |
ripekg:work/RIPEW7882272F2A6FA8D6Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
rdf:type |
owl:Thing |
ripekg:work/RIPEW7882272F2A6FA8D6Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
rdf:type |
prov:Entity |
ripekg:work/RIPEW7882272F2A6FA8D6Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial |
rdf:type |
ripe:WorkWork |